NxStage clears US hurdle in Medisystems acquisition:
This article was originally published in Clinica
Executive Summary
US antitrust authorities have completed a review of NxStage Medical's proposed buyout of its long-term business partner Medisystems Corporation, bringing NxStage closer to purchasing the developer of disposables used in dialysis and blood treatment. The firm says it has begun to implement organisational changes in anticipation of the transaction, expected to close during the fourth quarter of 2007. Lawrence, Massachusetts-based NxStage has promoted that Michael Webb to the newly-created position of senior vice-president of quality, regulatory and clinical affairs, whereas, upon the closing of the deal, Phil Licari will resign as senior vice-president and chief operating officer to pursue other opportunities. The deal, signed in June, is valued at around $78.7m (see Clinica No 1259, p 18).
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.